Walter Gratzer, Biophysical Chemist and Science Writer, Dies at 89
His career bridged impactful research in molecular biology and biochemistry with prolific science writing for academic and nonacademic audiences alike. (Source: The Scientist)
Source: The Scientist - November 23, 2021 Category: Science Tags: News & Opinion Source Type: news
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cranberry juice won ’t cut it: UTIs and the potential for repurposing drugs
The winning essay in the Max Perutz science writing award 2021, published below, was written by Vicky Bennett from the department of biology and biochemistry at Bath UniversityIn May, PhD students who are funded by the Medical Research Council (MRC) were invited to enter theMax Perutz science writing award 2021 and write a compelling piece about their research for the non-scientific reader.From the many entries received, the 10 that made the shortlist covered diverse topics, including dementia, childhood adversity, the role of genes in schizophrenia and the use of hypnosis to treat psychosis.Continue reading... (Source: Gu...
Source: Guardian Unlimited Science - November 6, 2021 Category: Science Authors: The Observer Tags: Science Medical research Antibiotics Health Awards and prizes Source Type: news
With CEO hire, this biotech boasts an all-women C-suite
Three months after publicly launching, Kojin Therapeutics has named a managing partner at the Dana-Farber Cancer Institute as its first CEO.
With the addition of Luba Greenwood's, Kojin now boasts an executive team made up entirely of women — a rarity in the male-dominated field of life sciences. Johnson& Johnson (NYSE: JNJ) veteran Kay Ahn is the startup's chief scientific officer, Lynn Abel is vice president of biochemistry and founder Vasanthi Viswanathan has stayed on as head of discovery … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 16, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news
With CEO hire, this biotech boasts an all-women C-suite
Three months after publicly launching, Kojin Therapeutics has named a managing partner at the Dana-Farber Cancer Institute as its first CEO.
With the addition of Luba Greenwood's, Kojin now boasts an executive team made up entirely of women — a rarity in the male-dominated field of life sciences. Johnson& Johnson (NYSE: JNJ) veteran Kay Ahn is the startup's chief scientific officer, Lynn Abel is vice president of biochemistry and founder Vasanthi Viswanathan has stayed on as head of discovery … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 16, 2021 Category: American Health Authors: Rowan Walrath Source Type: news
Collaborative COVID-19 lockdown effort delivers major boost for vaccine innovation in Bristol
Faster vaccine development could be a step closer thanks to £ 4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer ™ . Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya. (Source: University of Bristol news)
Source: University of Bristol news - October 7, 2021 Category: Universities & Medical Training Tags: Announcements, Business and Enterprise, Grants and Awards, Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Life Sciences, Faculty of Life Sciences, School of Biochemistry, Faculty Source Type: news
Oxford Covid biotech firm makes stellar debut on London stock market
Shares of Oxford Nanopore close up 44%, giving co-founder paper fortune of £63mSee all our coronavirus coverageOxford Nanopore, whose DNA sequencing technology has been essential in tracking Covid-19 variants globally, has made a stellar stock market debut in London. A rise in its share price of as much as 47% has left the firm valued at almost £5bn.The flotation of the Oxford University spin-out has given its chief executive and co-founder, Gordon Sanghera, a fortune on paper of £63m.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 30, 2021 Category: Science Authors: Julia Kollewe Tags: IPOs FTSE Stock markets Nanotechnology Biochemistry and molecular biology Science University of Oxford Business UK news Source Type: news
Bristol retains Strategic Partnership with the BBSRC and ranks fourth for bioscience research funding
The BBSRC, one of the UK ’ s largest UK bioscience funders, has announced Bristol will retain its Strategic Partnership (SP) status. The decision was announced this month following BBSRC ’ s SP member triannual review. Bristol is one of only ten top-funded university partners with this status – which it has retained since 2012 recognising the University ’ s long-term record for excellence in biosciences research. (Source: University of Bristol news)
Source: University of Bristol news - September 30, 2021 Category: Universities & Medical Training Tags: Grants and Awards, Business and Enterprise, Research; Faculty of Life Sciences, Faculty of Life Sciences, School of Biological Sciences, Faculty of Life Sciences, School of Biochemistry, Faculty of Life Sciences, School of Cellular and Molecular Medicine, Source Type: news
Antibodies in breast milk remain for 10 months after Covid infection – study
Exclusive: Researchers believe such antibodies could be used to treat people with severe coronavirusCoronavirus – latest updatesSee all our coronavirus coverageBreastfeeding women who have been infected with Covid-19 continue to secrete virus-neutralising antibodies into their milk for up to 10 months, data suggests.Besides emphasising the important role breastfeeding could play in helping to protect infants from the disease, researchers believe that such antibodies could be used to treat people with severe Covid-19, preventing their condition from getting worse.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 27, 2021 Category: Science Authors: Linda Geddes Tags: Breastfeeding Coronavirus Science Infectious diseases Microbiology Immunology World news Medical research Biochemistry and molecular biology Source Type: news
Major advance in race for SARS-CoV-2 inhibitor drugs
A new advance towards the development of drugs specifically designed to inhibit a key SARS-CoV-2 enzyme is reported in the Royal Society of Chemistry's leading journal, Chemical Science. The international team, led by scientists from the Universities of Oxford and Bristol, has designed new peptide molecules and shown that they block (inhibit) the virus ’ s main protease [Mpro] - a prominent SARS-CoV-2 drug target. (Source: University of Bristol news)
Source: University of Bristol news - September 20, 2021 Category: Universities & Medical Training Tags: International, Research; Faculty of Science, Faculty of Science, School of Chemistry, Faculty of Life Sciences, Faculty of Life Sciences, School of Biochemistry; Press Release Source Type: news
Oxford Covid biotech firm plans £2.4bn flotation on LSE
Business founded in 2005 has won contracts worth £144m from the UK government during pandemicOxford Nanopore, whose Covid-19 technology wassnapped up by the UK government and used to track variants of the virus globally, has unveiled its plans to float in one of the biggest London debuts this year.The company, a startup spun out from Oxford University, hopes to exceed a £2.4bn valuation achieved at a fundraising round in May. It has laid out plans to tap into the growing genomic sequencing market, estimated to be worth $5.7bn globally. Its revenues more than doubled to £114m last year, from £52m in 2019. It is aiming t...
Source: Guardian Unlimited Science - September 9, 2021 Category: Science Authors: Julia Kollewe Tags: IPOs Biochemistry and molecular biology Coronavirus Nanotechnology University of Oxford Business Stock markets Science Infectious diseases Source Type: news
Neuroscience and the misperception of reality | Letter
As living creatures, we are exquisitely evolved to interact with the world through perception, saysDavid HughesGaia Vince, reviewing Anil Seth ’s Being You: A New Science of Consciousness (The exhilarating new science of consciousness, 25 August), extols the thesis that because our perception of the world is a complex physical process, perception is itself a “hallucination” and “a big lie created by our deceptive brains”. But when we consider that dogs hear sounds we don’t, flies look through compound eyes, birds navigate using inbuilt GPS, it does seem perverse to claim that the very physicality of being alive...
Source: Guardian Unlimited Science - September 3, 2021 Category: Science Authors: Letters Tags: Neuroscience Psychology Science and nature books Consciousness Source Type: news
Edmond Fischer, Biochemist and Nobel Laureate, Dies at 101
Fischer was recognized for his work with reversible protein phosphorylation. (Source: The Scientist)
Source: The Scientist - August 31, 2021 Category: Science Tags: News & Opinion Source Type: news
Henry Higgs Named the John La Porte Given Professor in Cytology
Henry N. Higgs, PhD, a nationally known researcher and professor of biochemistry and cell biology at Dartmouth’s Geisel School of Medicine, has been named the John La Porte Given Professor in Cytology. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - August 11, 2021 Category: Hospital Management Authors: Timothy Dean Tags: News Henry Higgs professorship Source Type: news
